Ocuphire Pharma, Inc. announced the appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer, effective November 1, 2023. Dr. Magrath succeeds Rick Rodgers, M.B.A., Interim Chief Executive Officer since April 2023. Mr. Rodgers will remain on the company?s Board of Directors.

Dr. Magrath was most recently the Chief Executive Officer of Lexitas Pharmaceutical Services, Inc., where he led the company through significant growth, broadened its business lines, and increased revenue substantially. He successfully led Lexitas through the acquisition and integration process with QHP Capital, creating a premier ophthalmology contract research organization and generating significant value for investors. Prior to Lexitas, Dr. Magrath served as Medical Director to Hovione Pharmaceuticals, LLC, responsible for developing and advancing the companys proprietary drugs in dermatology, ophthalmology and respiratory.

He has served on many industry advisory boards and has authored numerous peer-reviewed publications. Dr. Magrath received his medical degree from the Medical University of South Carolina, M.B.A. from The Citadel - The Military College of South Carolina, M.S. in Applied Economics from Johns Hopkins University, and B.S. in Biological Chemistry from Clemson University.